Use of hiPSC-Derived Cardiomyocytes to Rule Out Proarrhythmic Effects of Drugs: The Case of Hydroxychloroquine in COVID-19.

MLA

Sala, Luca, et al. “Use of HiPSC-Derived Cardiomyocytes to Rule Out Proarrhythmic Effects of Drugs: The Case of Hydroxychloroquine in COVID-19.” Frontiers in Physiology, vol. 12, Jan. 2022, p. 730127. EBSCOhost, https://doi.org/10.3389/fphys.2021.730127.

APA

Sala, L., Leonov, V., Mura, M., Giannetti, F., Khudiakov, A., Moretti, A., Crotti, L., Gnecchi, M., & Schwartz, P. J. (2022). Use of hiPSC-Derived Cardiomyocytes to Rule Out Proarrhythmic Effects of Drugs: The Case of Hydroxychloroquine in COVID-19. Frontiers in Physiology, 12, 730127. https://doi.org/10.3389/fphys.2021.730127

Chicago

Sala, Luca, Vladislav Leonov, Manuela Mura, Federica Giannetti, Aleksandr Khudiakov, Alessandra Moretti, Lia Crotti, Massimiliano Gnecchi, and Peter J Schwartz. 2022. “Use of HiPSC-Derived Cardiomyocytes to Rule Out Proarrhythmic Effects of Drugs: The Case of Hydroxychloroquine in COVID-19.” Frontiers in Physiology 12 (January): 730127. doi:10.3389/fphys.2021.730127.